Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 8, 2011

BioCat to Distribute SwitchGear Genomics’ LightSwitch Luciferase Assay System

  • SwitchGear Genomics signed an agreement under which all components of its LightSwitch Luciferase Assay System™ will be promoted and sold by BioCat in Austria, Germany, and Switzerland. SwitchGear will provide full sales, marketing, and technical support for the LightSwitch Luciferase Assay System, which was launched last month.

    “The agreement furthers our effort to providing a full and cost-effective reporter assay solution using new channels,” Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics, said in a statement.

    The LightSwitch system is a collection of more than 30,000 cloned regulatory elements from the human genome, including 18,000 promoters and 12,000 3’UTRs luciferase reporters. The human assay-ready GoClone™ promoters are paired with optimized LightSwitch luciferase assay reagents. The goal is to measure transcriptional activation and translational efficiency in living cells.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »